amivantamab in patients with egfr ex20ins-mutated nsclc
Published 1 year ago • 518 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
4:27
amivantamab shows robust efficacy in post-platinum therapy patients with egfr ex20ins nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
3:01
update from chrysalis: amivantamab in patients with nsclc with met exon 14 skipping mutation
-
1:36
chrysalis: amivantamab for egfr exon 20 insertion mutant nsclc
-
2:07
papillon: amivantamab plus chemotherapy in nsclc with egfr exon 20 insertions
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
1:27
papillon phase iii primary results: amivantamab chemo vs chemo in egfr exon 20 nsclc
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
1:34
pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
1:18
amivantamab for nsclc with met exon 14 skipping mutations
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
2:04
mariposa-2: amivantamab chemo (± lazertinib) vs chemo in egfr-mutated nsclc post-osimertinib
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20